On October 14, 2026 Nusano, a physics company transforming the production of radioisotopes, and Primo Biotechnology, a Taiwan-based radiopharmaceutical developer, reported a multi-isotope supply agreement to support Primo’s radiotheranostic product pipeline and strengthen access to critical medical isotopes used in the development of targeted cancer therapies.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The agreement gives Primo access to Nusano-produced radioisotopes, including lutetium-177, actinium-225, indium-111, zirconium-89, and terbium-161.
"At Primo, we are working to advance innovative radiotheranostic medicines that can improve the lives of cancer patients," said Dr. Ya-Yao Huang, Chairman and CEO of Primo Biotechnology. "That work depends on reliable access to critical medical isotopes, and this agreement with Nusano strengthens our ability to develop and deliver next-generation radiotherapeutics with greater confidence."
Nusano’s radioisotope production platform combines established technologies from universities and world-class research centers with the company’s patented particle acceleration technology. The result is one of the first significant advancements in radioisotope production in decades: a smaller, more efficient platform capable of simultaneously manufacturing up to 12 different radioisotopes.
"Radiotherapeutic developers need dependable access to radioisotopes to move programs from discovery to clinical impact," said Howard Lewin, Nusano co-founder and Chief Product Development Officer. "Nusano’s production platform is built to deliver that reliability, with the capacity and flexibility to grow and adapt with our customers’ needs. We are proud to establish a supplier relationship with Primo and look forward to supporting their pipeline of next-generation cancer therapies."
(Press release, Nusano, OCT 14, 2026, View Source [SID1234673447])